Syndax Pharmaceuticals (SNDX) Net Interest Income — Quarterly & Annual

Screener

Net Interest Income at other companies

Northern TrustNTRS

$654M+15.1%

NexPoint Real Estate FinanceNREF

$15.3M+32.9%

LFT

Lument Finance TrustLFT

$5.7M-26.3%

Tapestry, Inc.TPR

-$13.1M+14.9%

Synchrony FinancialSYF

$4.64B+3.8%

Academy Sports and OutdoorsASO

-$8.99M+0.6%

Segments

By segment

Biopharmaceutical Cancer Therapeutics-$3.56M+50.4%

Other financials

Income statement

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

Market cap$1.82B+69.0%

Enterprise value$2.04B+57.0%

P/S8.4×-5.4×

Profitability

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×